Source: Annual Congress 2011 - Mechanisms and outcomes of infective exacerbations of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Wilson, A. Anzueto, M. Miravitlles, P. Arvis, J. Alder, D. Haverstock, M. Trajanovic, S. Sethi (London, United Kingdom; San Antonio, Montville, Buffalo, United States Of America; Barcelona, Spain; Loos, France; Toronto, Canada). Late-breaking abstract: Moxifloxacin (MXF) vs amoxicillin/clavulanic acid (AMC) in acute exacerbations of COPD (AECOPD): Results of a large clinical trial with a novel endpoint. Eur Respir J 2011; 38: Suppl. 55, 195

Member's Comments

No comment yet.

Related content which might interest you: Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results Source: Eur Respir J 2012; 40: 17-27 Year: 2012 Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002 Short and long-term outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): The MOSAIC study Source: Eur Respir J 2003; 22: Suppl. 45, 566s Year: 2003 Short-term efficacy of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): A multivariate analysis from the MOSAIC study Source: Eur Respir J 2003; 22: Suppl. 45, 351s Year: 2003 Late Breaking Abstract - Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid - Data from 38,820 outpatients. Source: International Congress 2019 – Comorbidities galore in respiratory patients Year: 2019 Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis: the  BEST-2 trial Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment Year: 2018 IV azithromycin (AZM)/ceftriaxone (CEF) followed by PO AZM vs IV levofloxacin (LEV) followed by PO LEV in treatment of hospitalized patients with community acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003 Lower overall healthcare costs with telithromycin (TEL) versus clarithromycin (CLA) in community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 152s Year: 2003 Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 674s Year: 2007 Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval Source: Eur Respir J 2004; 24: 947-953 Year: 2004 Effectiveness of azithromycin (AZ) in patients with community-acquired pneumonia (CAP): an evidenced-based meta-analysis of randomized controlled trials (RCTs) Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001 Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP) Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD Year: 2003 Evaluation of moxifloxacin (MXF) as empiric antibiotic therapy of CAP outpatients: A multicenter prospective study Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 The efficiency of moxifloxacin (MOX) in community-acquired pneumonias (CAP) treatment while the initial antibacterial therapy (IAT) was inefficient Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 Greatest International ANti-infective Trial (GIANT) – the German cohort: moxifloxacin treatment provides short- and long-term benefits in AECB patients Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Antibacterial activity of telithromycin (TEL) and comparators against bacterial pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 641s Year: 2004 Procalcitonin-guided antibiotic therapy in acute exacerbations of COPD (AECOPD): a randomised trial - The ProCOLD Study Source: Eur Respir J 2005; 26: Suppl. 49, 464s Year: 2005